Pfizer (NYSE:PFE) Releases FY 2025 Earnings Guidance

Pfizer (NYSE:PFE) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of 3.000-3.150 for the period, compared to the consensus estimate of 3.150. The company issued revenue guidance of $62.0 billion-$62.0 billion, compared to the consensus revenue estimate of $62.6 billion.

Pfizer Stock Performance

NYSE:PFE opened at $24.89 on Wednesday. The stock has a 50 day simple moving average of $25.12 and a 200 day simple moving average of $24.88. The stock has a market cap of $141.49 billion, a P/E ratio of 14.47 and a beta of 0.46. Pfizer has a 1-year low of $20.92 and a 1-year high of $27.69. The company has a current ratio of 1.28, a quick ratio of 0.97 and a debt-to-equity ratio of 0.62.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 EPS for the quarter, beating analysts’ consensus estimates of $0.79 by $0.08. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.The firm had revenue of $16.65 billion for the quarter, compared to analyst estimates of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Research analysts anticipate that Pfizer will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, January 23rd will be issued a $0.43 dividend. The ex-dividend date of this dividend is Friday, January 23rd. This represents a $1.72 dividend on an annualized basis and a yield of 6.9%. Pfizer’s payout ratio is currently 100.00%.

Analyst Ratings Changes

PFE has been the topic of a number of analyst reports. The Goldman Sachs Group restated a “neutral” rating and set a $26.00 target price on shares of Pfizer in a research report on Wednesday, November 5th. BMO Capital Markets reissued an “outperform” rating on shares of Pfizer in a research report on Wednesday, December 10th. HSBC reaffirmed a “buy” rating and issued a $29.00 price objective on shares of Pfizer in a report on Wednesday, December 10th. Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a report on Wednesday, October 8th. Finally, Citigroup assumed coverage on Pfizer in a research report on Tuesday, December 2nd. They issued a “neutral” rating and a $26.00 price target on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $28.06.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Longer-term growth narrative: commentary suggesting Pfizer is pursuing GLP‑1 and other high‑yield opportunities that could support future earnings and income-focused investor appeal. Should You Forget Novo Nordisk and Buy This Magnificent High-Yield Drug Stock Instead?
• Neutral Sentiment: Market/price context: coverage noting PFE slid while broad markets rose — signals the move is driven by company-specific news rather than sector weakness; trading volume slightly below average. Pfizer (PFE) Stock Slides as Market Rises: Facts to Know Before You Trade
• Negative Sentiment: Safety shock: Pfizer reported a patient death in a long‑term extension study involving Hympavzi (marstacimab). The company has opened a safety review and is reassessing related surgical protocols; the working theory reported by some outlets is a thrombotic event. This is the primary near‑term catalyst driving the stock lower due to potential trial, label or usage impacts and increased regulatory scrutiny. Pfizer says patient dies after receiving hemophilia drug in trial
• Negative Sentiment: Analyst reaction: coverage notes at least one downgrade to “Hold” tied to lower 2026 revenue guidance and uncertainty about growth trajectories — adds downward pressure by adjusting near‑term expectations and investor sentiment. Pfizer: Downgrade To ‘Hold’ On Lower 2026 Revenue Guidance And Potential Growth Tracks

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. State Street Corp lifted its holdings in shares of Pfizer by 0.9% in the third quarter. State Street Corp now owns 299,087,408 shares of the biopharmaceutical company’s stock worth $7,620,747,000 after acquiring an additional 2,786,098 shares during the last quarter. Northern Trust Corp increased its position in Pfizer by 1.4% during the 3rd quarter. Northern Trust Corp now owns 64,019,807 shares of the biopharmaceutical company’s stock worth $1,631,225,000 after purchasing an additional 869,175 shares in the last quarter. Amundi lifted its stake in Pfizer by 10.8% in the 3rd quarter. Amundi now owns 41,490,929 shares of the biopharmaceutical company’s stock valued at $1,096,380,000 after purchasing an additional 4,043,413 shares during the last quarter. Invesco Ltd. boosted its position in Pfizer by 3.7% in the third quarter. Invesco Ltd. now owns 30,335,842 shares of the biopharmaceutical company’s stock valued at $772,957,000 after buying an additional 1,085,701 shares in the last quarter. Finally, Unisphere Establishment grew its stake in shares of Pfizer by 13.8% during the third quarter. Unisphere Establishment now owns 14,400,000 shares of the biopharmaceutical company’s stock worth $366,912,000 after buying an additional 1,750,000 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.